Thus, it is possible that OCT3 (and/or PMAT) expression and/or function is upregulated in juveniles/adolescents, thereby decreasing efficacy of SSRIs to treat depression in children/teenagers. This evidence concerns the gene SLC22A3 and depressive disorder.